Second participant enrolls in clinical trial of coronavirus treatment
A second participant has enrolled in the UNMC clinical trial of an experimental treatment for COVID-19
Eight of the original 15 Americans from the Diamond Princess cruise ship remain on the UNMC/ Nebraska Medical Center campus. One guest – cleared yesterday – left the National Quarantine Unit this morning.
One person continues to be treated in the Nebraska Biocontainment Unit, and seven are being monitored in the quarantine unit.
COVID-19 cases in the U.S. stand at more than 160, with 11 deaths. Globally, cases have reached nearly 97,000 and more than 3,300 deaths.
As cases continue to increase in the U.S., it is important for everyone to create their family plan and for health care facilities to update pandemic plans. The Centers for Disease Control and Prevention offers these recommendations.
A second participant has enrolled in the UNMC clinical trial of an experimental treatment for COVID-19. The trial at UNMC is led by Andre Kalil, MD, and is sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.